More research is needed to establish a standardization of SPECT/CT TPs and warrant recommendations on which TAC fit model is appropriate to use particularly for tumor dosimetry after 177Lu-PSMA radioligand therapy. The gene discussed is FOLH1; the disease is neoplasm.